TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05046886

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized
Description: Participants are instructed to follow a Mediterranean-style diet. Dietary counseling is paired with SCT-based behavioral counseling, which focuses on the role played by self-referent thought in the maintenance of behavior change. Self-efficacy (e.g., the participant's confidence in their ability to engage in healthier behavior) is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states. Participants self-monitor their diet using a mobile app and receive real-time feedback from the app on macronutrient distribution.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized
Description: Participants are instructed to follow a Mediterranean-style diet. Dietary counseling is paired with SCT-based behavioral counseling, which focuses on the role played by self-referent thought in the maintenance of behavior change. Self-efficacy (e.g., the participant's confidence in their ability to engage in healthier behavior) is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states. Participants self-monitor their diet using a mobile app and receive real-time feedback from the app on macronutrient distribution.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Control (UCC)
Description: Participants are instructed to follow a Mediterranean-style diet,

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Control (UCC)
Description: Participants are instructed to follow a Mediterranean-style diet,

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care Control (UCC)
Description: Participants are instructed to follow a Mediterranean-style diet,

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Guidance to Minimize Postprandial Glycemic Response (PPGR)
Description: Participants are instructed to follow a Mediterranean-style diet. Dietary counseling is paired with SCT-based behavioral counseling, which focuses on the role played by self-referent thought in the maintenance of behavior change. Self-efficacy (e.g., the participant's confidence in their ability to engage in healthier behavior) is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states. Participants self-monitor their diet using a mobile app and receive real-time feedback from the app on their predicted PPGR to meals and snacks at the time they enter them into their smart phone. PPGR predictions will be generated from a gut microbiome-based machine learning algorithm.
Study: NCT06561360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cladribine
Description: Cladribine IV on days 1-5 concurrently with rituximab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab on days 1-5 concurrently with rituximab.
Study: NCT04948541

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: osa treatment
Description: different treatments can be included

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no treatment
Description: no treatment was undergone
Study: NCT05670041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensified follow-up
Description: Early, intensified follow-up after discharge from TAVI-procedure.
Study: NCT05888389

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cranial Nerve Block Anesthesia Combined With Sedative Anesthesia
Description: Patients in the nerve block anesthesia combined with sedative anesthesia group will first receive cranial nerve blocks under standard monitoring. At the same time, intravenous dexmedetomidine infusion is started for sedation at a rate of 2-4ug/kg for 10 minutes, followed by a continuous infusion of 0.5-1ug/kg/h until the Richmond Agitation-Sedation Scale (RASS) of -3.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: Patients will be induced with propofol or etomidate, sufentanil , rocuronium or cisatracurium .
Study: NCT05927376

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Western diet
Description: All foods, meal plans and instructions provided.
Study: NCT05813626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab (240 mg Q3W for 3 cycles) combine with chemotherapy
Study: NCT06004284

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Ergonomics training will be given to each of the control group participants individually. The content of this training will include what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk fa

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise group
Description: The exercise training program will be applied for 8 weeks, 3 days a week and for an average of 20-30 minutes. After the maneuver is taught, stretching exercises lasting 5 minutes for warm-up purposes and posture and core exercises lasting 25 minutes will be taught. Among the stretching exercises, quadratus lumborum stretching, hamstring stretching, erector spina stretching, hip extensor stretching exercises will be applied. Posterior pelvic tilt exercise will be performed as a control and smoothing exercise for the vertebrae of the lumbar and pelvic region. Among the core stabilization exercises, bridging, plank, plank in side lying, abdominal strengthening, cross arm leg lifting exercises in crawling position will be performed. Each exercise position will be required to be maintained for 8 seconds and to do 10-15 repetitions.
Study: NCT04887090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture and Drug Compound Technology
Description: Before operation: The points of the meridian: Hegu, Neiguan, Chize, Zusanli, both sides are taken. TEAS (transcutaneous electrical acupoints stimulation) was performed every day for three days before the operation, using the Han's acupoint nerve stimulator to adjust the density and density waveforms at a frequency of 2/100 Hz (Hz). Current intensity is 10mA, and all acupuncture points are continuously stimulated for 30 minutes. During the operation: take the acupoints Hegu, Neiguan, Houxi, and Zhigou on both sides and give TEAS 30 minutes before induction of anesthesia. The stimulation intensity and frequency are the same as those before the operation until the end of the operation. Postoperative: Take the acupoints Chize, Waiguan, Taichong, and Yanglingquan, and take both sides. TEAS will be performed every 12 hours from the first day after surgery. Each treatment is 30 minutes until 48 hours after surgery. The intensity and frequency are the same as before surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine perioperative management
Description: Comprehensive evaluation of cardiopulmonary function, preparation of respiratory tract, active treatment of coexisting diseases before operation, correction of water and electrolyte disorders and hypoproteinemia before operation. To prevent cross-infection during the operation, the intraoperative blood volume should be supplemented within the tolerance of cardiac function, the tissue perfusion should be sufficient, and the infusion should be uniform. Strengthen respiratory care after operation, prevent cardiovascular complications, pay attention to the speed and amount of blood transfusion, encourage early activities, promote lung expansion and prevent thrombophlebitis.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine perioperative management
Description: Comprehensive evaluation of cardiopulmonary function, preparation of respiratory tract, active treatment of coexisting diseases before operation, correction of water and electrolyte disorders and hypoproteinemia before operation. To prevent cross-infection during the operation, the intraoperative blood volume should be supplemented within the tolerance of cardiac function, the tissue perfusion should be sufficient, and the infusion should be uniform. Strengthen respiratory care after operation, prevent cardiovascular complications, pay attention to the speed and amount of blood transfusion, encourage early activities, promote lung expansion and prevent thrombophlebitis.
Study: NCT05036057

Intervention type: OTHER
Intervention: Questionnaire
Description: Patients will do the Individual Knowledge Statement Questionnaire of Chronic Obstructive Pulmonary Disease (COPD), the COPD Assesment Test (CAT), the Saint George Respiratory Disease Questionnaire (SGRQ), the Charlson Comorbidity Index, and will rate the disease and general knowledge level on a numerical scale.~Proxies of patients will do the Individual Knowledge Statement Questionnaire of Chronic Obstructive Pulmonary Disease (COPD) and will rate the disease and general knowledge level on a numerical scale.
Study: NCT04934189

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Empowerment Self Defense Training
Description: We have contracted with Prepare, Inc., the New York City chapter of IMPACT International to deliver the tailored ESD violence prevention intervention. IMPACT is an international ESD violence prevention organization with chapters across the United States. Prepare, Inc. will provide facilitators who have completed IMPACT's nationally standardized ESD violence prevention program requirements that include receipt of over 100 hours of training. IMPACT training is open to trans and cisgender women. The extensive training of IMPACT facilitators promotes intervention efficacy, while the risk of potential bias conferred by their experience with a pre-existing curriculum is mitigated by our community-engaged approach (i.e.,TW community members, service providers, and scientists \[PI and Co-I\] collectively shape the content of the final tailored ESD intervention, and TW co-facilitators will be present in every training session).
Study: NCT05390151

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser treatment of anal fistula
Description: using a radial laserprobe to treat transsphincteric fistula

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RAF
Description: current golden standard in transsphincteric fistula surgery
Study: NCT05044936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oil
Description: The dose that will be used for each administration of CBD will be 0.5mg/kg of body mass. As there are no recommendations for CBD from the FDA or through previous research in humans, and especially for CBD cream, the dosage is based on the United Kingdom's governing body recommending maximal amounts of CBD ingestion being 1 mg/kg per day. Further, the practical amount that companies recommend is anywhere from a pea size to a handful, which can range from high and low amounts. Using 0.5mg/kg of body mass allows for a moderate use of the lotion, as well as leaving extra quantities throughout the day should people want to use CBD outside of their post-workout recovery strategies outside of a laboratory setting. To convert the amount of CBD to the amount of lotion, we will divide the amount of CBD (0.5 mg/kg) by 4.85 (the amount of mg of CBD per gram of lotion). This will calculate the amount (in grams) of lotion each participant will receive.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Participants will complete eccentric-based leg press (4-s lowering phase and 1-s upward phase) for 10 sets of 8 repetitions at 70% 1RM in order to induce muscle damage using a leg press machine. Three minutes of rest will be permitted between sets. Following the 10th leg press, participants will complete 4 sets of 20 consecutive plyometric lunges using only their body weight. Two minutes of rest will be permitted between sets. The muscle damaging protocol will be done upon completion of the 4th set of plyometric lunges.
Study: NCT05855902

Intervention type: BEHAVIORAL
Intervention: group art therapy
Description: Art therapy will be offered in a weekly 1.5 hour group. Clients are provided a prompt and then asked to express their feelings using art, such as drawing/painting/etc.
Study: NCT01435434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the Sepax is a tool to standardize adult stem cell. Ignite ®ICS injectable scaffold manufactured by Wright Medical Technology.
Study: NCT05332977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD-CAM fabricated provisional prosthesis
Description: Insertion of CAD-CAM fabricated provisional prosthesis (CAD-CAM) on axially placed or titled implants for rehabilitation of atrophic maxilla

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DC (denture conversion) provisional prosthesis
Description: Insertion of denture conversion (DC) provisional prosthesis on axially placed or titled implants for rehabilitation of atrophic maxilla
Study: NCT05907460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transesophageal echocardiography examination during cardiopulmonary resuscitation
Description: Perform transesophageal echocardiography in patients with out-of-hospital cardiac arrest during cardiopulmonary resuscitation and adjust the chest compression site to compress the left ventricle and avoid left ventricular outflow tract.
Study: NCT06502964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALTO-101
Description: 4.5 mg ALTO-101 patches

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALTO-101 Transdermal Delivery System
Description: 4.5 mg ALTO-101 transdermal delivery system

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive placebo patches

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Transdermal Delivery System
Description: Placebo transdermal delivery system
Study: NCT04868604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-SAR-bisPSMA
Description: 64Cu-SAR-bisPSMA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 67Cu-SAR-bisPSMA
Description: 67Cu-SAR-bisPSMA
Study: NCT05104567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THOR-707
Description: Solution for infusion: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THOR-707
Description: Solution for infusion: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THOR-707
Description: Solution for infusion: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THOR-707
Description: Solution for infusion: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THOR-707
Description: Solution for infusion: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THOR-707
Description: Solution for infusion: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THOR-707
Description: Solution for infusion: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Solution for infusion: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Solution for infusion: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Solution for infusion: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Solution for infusion: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Solution for infusion: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Solution for infusion: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Solution for infusion: intravenous infusion
Study: NCT04652908

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix
Description: As in the current standard fetal surgery, under sonographic guidance, initial uterine entry will be accomplished by uterine stapling device or similar. The fetus will be given an intramuscular injection of pain medications and paralytic. The myelomeningocele will be closed in a standardized manner under magnification. As in the standard fetal operation, the spinal cord will be dissected from surrounding tissue and allowed to drop into the spinal canal. The PMSC-ECM product will then be tailored to the size of the spinal cord and applied topically, cell side down. The PMSC-ECM product will be sutured in place to the dura. Finally, the fetal skin will be closed in the standard fashion. The amniotic fluid volume will be replaced and antibiotics will be added. The uterus will be closed. The abdominal fascial layer and skin will be closed in routine fashion.

Intervention type: OTHER
Group type: OTHER
Intervention: Untreated contemporaneous cohort
Description: The addition of a non-PMSC treated cohort, the untreated contemporaneous cohort, has been added at the request of the FDA to provide contemporaneous patients for validation of the continued relevance of use of the outcomes of the MOMS trial as the comparison arm for the Phase 2a portion of the study.
Study: NCT05026905

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine 1000 mg
Description: Gemcitabine 800mg/m2 in N/S 250ml over 30 minutes (or fixed dose rate 10 mg/m2/min) IV infusion on day 1 repeated every 14 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine 1000 mg
Description: Gemcitabine 800mg/m2 in N/S 250ml over 30 minutes (or fixed dose rate 10 mg/m2/min) IV infusion on day 1 repeated every 14 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Nab paclitaxel
Description: Nab-paclitaxel 125mg/m2 over 30 minutes IV infusion on day 1 repeated every 14 days, followed by Gemcitabine

Intervention type: DRUG
Group type: OTHER
Intervention: Nab paclitaxel
Description: Nab-paclitaxel 125mg/m2 over 30 minutes IV infusion on day 1 repeated every 14 days, followed by Gemcitabine

Intervention type: DRUG
Group type: OTHER
Intervention: S1
Description: S-1 orally 60-100 mg/day day 1 to 7 on in a 2-week cycle. The dose of S-1 is defined as follows:~* BSA \< 1.25 m2: 60 mg/day~* 1.25 m2 ≤ BSA \< 1.5 m2: 80 mg/day~* BSA ≥ 1.5 m2: 100 mg/day

Intervention type: DRUG
Group type: OTHER
Intervention: leucovorin
Description: leucovorin 30mg BID day 1 to 7 on in a 2-week cycle

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: Oxaliplatin 75mg/m2 in 250 mL of D5W over 120 minutes IV infusion on day 1 repeated every 14 days
Study: NCT06426472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based support program
Description: Web-based support program for infertile women with failed IVF experience
Study: NCT05703880

Intervention type: DRUG
Intervention: Finerenone (Kerendia, BAY948862)
Description: Retrospective cohort analysis using United States Optum EHR data and OM1 RWDC databases.
Study: NCT06653608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nano-reinforced calcium hydroxide medicament
Description: Group A (Calcium hydroxide intracanal medicament reinforced with jasminum derived- titania nanoparticles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide without nanoparicles
Description: Group B ( Calcium hydroxide medicament without nanoparticles)
Study: NCT05697029

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tetrandrine
Description: tetrandrine TID for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrandrine
Description: tetrandrine TID for 28 days
Study: NCT05016141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: digital fall prevention program
Description: The participants will receive a digital fall prevention program consisting of fall risk reduction education (modified Matter of Balance), Otago Exercise Program, Personalized S.M.A.R.T Goals, and will use the app to keep track of their health and health events, including falls.
Study: NCT06662448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAVIR Alpha Synch mobile (SASm)
Description: The SAVIR Alpha Synch mobile is a device first used in office and then intended to be used for the home therapy of the visual system with non-invasive electrical stimulation.
Study: NCT06665178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Administer Sacituzumab Govitecan (SG) at 10 mg/kg as an intravenous (IV) infusion on Days 1 and 8 of a 21-day cycle. SG should not be administered as an IV push or bolus.
Study: NCT06665295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THRIVE-CAR-T
Description: The intervention will begin several weeks prior to CAR-T cell therapy and will continue up until 30 days post CAR-T cell therapy. THRIVE-CAR-T is an educational and interactive digital application on an iPad for patients as they navigate receiving CAR-T. THRIVE-CAR-T is self-administered and provides education about the CAR-T cell therapy process, with several features to promote coping skills training informed by various well-established supportive psychotherapy strategies (e.g., cognitive behavior therapy, mindfulness, positive psychology), engagement, and health behavior change including gamification strategies, videos of patients who received CAR-T, and optional content.
Study: NCT06668675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A serious game known as the 'Happy Heart' will be used as the intervention.
Description: The serious game known as 'Happy Heart' is a mobile game used for educational purpose in addition to entertainment. It focuses on healthy habits for the heart and is aimed at improving knowledge on diet and physical activity among school-going adolescents.~The game is developed in collaboration with the game development team from the School of Informatics, University of Skövde and the health team from Kathmandu Medical College, Nepal.

Intervention type: OTHER
Group type: OTHER
Intervention: A serious game known as the 'Happy Heart' will be used as the intervention.
Description: The serious game known as 'Happy Heart' is a mobile game used for educational purpose in addition to entertainment. It focuses on healthy habits for the heart and is aimed at improving knowledge on diet and physical activity among school-going adolescents.~The game is developed in collaboration with the game development team from the School of Informatics, University of Skövde and the health team from Kathmandu Medical College, Nepal.
Study: NCT06667609

Intervention type: OTHER
Intervention: Any treatments regimen
Description: Participants may receive any treatments in accordance with standard clinical practice, based on physicians' recommendations and patients' preferences.
Study: NCT06334653

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: exercise
Description: acute exercise bout

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: acute exercise bout